Amicus Therapeutics, Inc. (NASDAQ:FOLD) had its price target increased by equities researchers at Chardan Capital from $12.50 to $17.50 in a research report issued on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Chardan Capital’s target price would suggest a potential upside of 39.11% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird reaffirmed an “outperform” rating and set a $12.00 price target (up from $10.00) on shares of Amicus Therapeutics in a research note on Wednesday, May 17th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $15.00 price target (up from $13.00) on shares of Amicus Therapeutics in a research note on Wednesday. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 12th. BidaskClub raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Finally, ValuEngine raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $14.58.

Shares of Amicus Therapeutics (NASDAQ FOLD) opened at 12.58 on Thursday. The stock’s 50 day moving average is $12.10 and its 200-day moving average is $8.42. The stock’s market capitalization is $1.80 billion. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $14.05. Amicus Therapeutics also was the recipient of unusually large options trading activity on Monday. Stock traders bought 11,013 call options on the company. This is an increase of 666% compared to the typical volume of 1,438 call options.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 672.48% and a negative return on equity of 66.85%. The firm had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. During the same period in the previous year, the company earned ($0.40) EPS. On average, analysts expect that Amicus Therapeutics will post ($1.41) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/amicus-therapeutics-inc-fold-pt-raised-to-17-50/1467559.html.

In related news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the stock in a transaction on Thursday, July 13th. The stock was bought at an average cost of $12.25 per share, with a total value of $18,375,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Hung Do sold 29,914 shares of the business’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $8.00, for a total transaction of $239,312.00. Following the completion of the sale, the insider now directly owns 474,438 shares of the company’s stock, valued at $3,795,504. The disclosure for this sale can be found here. 3.40% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in FOLD. Wellington Management Group LLP boosted its stake in Amicus Therapeutics by 358.4% in the first quarter. Wellington Management Group LLP now owns 5,341,132 shares of the biopharmaceutical company’s stock valued at $38,083,000 after buying an additional 4,175,995 shares during the period. Morgan Stanley boosted its stake in Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after buying an additional 3,055,039 shares during the period. Point72 Asset Management L.P. bought a new stake in Amicus Therapeutics during the first quarter valued at about $21,394,000. Palo Alto Investors LLC boosted its stake in Amicus Therapeutics by 23.0% in the first quarter. Palo Alto Investors LLC now owns 7,882,988 shares of the biopharmaceutical company’s stock valued at $56,206,000 after buying an additional 1,472,958 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in Amicus Therapeutics during the first quarter valued at about $7,346,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.